Toll-like receptors gene polymorphisms may confer increased susceptibility to breast cancer development

Breast

Volumn 21, Issue 4, 2012, Pages 534-538

  Theodoropoulos, George E ^a   Saridakis, Vasilios ^a   Karantanos, Theodoros ^a   Michalopoulos, Nikolaos V ^a   Zagouri, Flora ^a   Kontogianni, Panagiota ^a   Lymperi, Maria ^b   Gazouli, Maria ^b   Zografos, George C ^a  

^a HIPPOKRATION HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Breast cancer; Polymorphisms; Toll like receptors

Indexed keywords

TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4;

ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; BREAST CANCER; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; FEMALE; GENE; GENE DELETION; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROMOTER REGION; TLR2 GENE; TLR4 GENE;

EID: 84863875150     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2012.04.001     Document Type: Article

References (32)

1. Kawai T., Akira S. TLR signaling. Cell Death Differ 2006, 13:816-825.
2. Igney F.H., Krammer P.H. Immune escape of tumors: apoptosis resistance and tumor counterattack. J Leukoc Biol 2002, 71:907-920.
3. Walker P.R., Saas P., Dietrich P.Y. Tumor expression of Fas ligand (CD95L) and the consequences. Curr Opin Immunol 1998, 10:564-572.
4. Schreibelt G., Tel J., Sliepen K.H., Benitez-Ribas D., Figdor C.G., Adema G.J., et al. Toll like receptor expression and function in human dendritic cell subsets: implications for dendritic cell-based anti-cancer immunotherapy. Cancer Immunol Immunother 2010, 59:1573-1582.
5. Liu H., Komai-Koma M., Xu D., Liew F.Y. Toll-like receptor 2 signaling modulates the functions of CD4+CD25+ regulatory T cells. Proc Natl Acad Sci U S A 2006, 103:7048-7053.
6. Kabelitz D. Expression and function of toll-like receptors in T lymphocytes. Curr Opin Immunol 2007, 19:39-45.
7. Huang B., Zhao J., Li H., He K.L., Chen Y., Chen S.H., et al. Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res 2005, 65:5009-5014.
8. Kelly M.G., Alvero A.B., Chen R., Silasi D.A., Abrahams V.M., Chan S., et al. TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res 2006, 66:3859-3868.
9. Xie W., Wang Y., Huang Y., Yang H., Wang J., Hu Z. Toll-like receptor 2 mediates invasion via activating NF-kappaB in MDA-MB-231 breast cancer cells. Biochem Biophys Res Commun 2009, 20:1027-1032.
10. Mantovani A., Allavena P., Sica A., Balkwill F. Cancer related inflammation. Nature 2008, 454:436-444.
11. Liao S.J., Zhou Y.H., Yuan Y., Li D., Wu F.H., Wang Q., et al. Triggering of toll-like receptor 4 on metastatic breast cancer cells promotes αvβ3-mediated adhesion and invasive migration. Breast Cancer Res Treat 2011, [Epub ahead of print].
12. Egunsola A.T., Zawislak C.L., Akuffo A.A., Chalmers S.A., Ewer J.C., Vail C.M., et al. Growth, metastasis, and expression of CCL2 and CCL5 by murine mammary carcinomas are dependent upon Myd88. Cell Immunol 2012, 272:220-229.
13. Sipponen P., Kekki M., Haapakoski J., Ihamaki T., Siurala M. Gastric cancer risk in chronic gastritis. Statistical calculations of cross-sectional data. Int J Cancer 1985, 35:173-177.
14. Nischalke H.D., Coenen M., Berger C., Aldenhoff K., Müller T., Berg T., et al. The toll-like receptor 2 (TLR2) -196 to -174 del/ins polymorphism affects viral loads and susceptibility to hepatocellular carcinoma in chronic hepatitis C. Int J Cancer 2011, [Epub ahead of print].
15. Tahara T., Arisawa T., Wang F., Shibata T., Nakamura M., Sakata M., et al. Toll-like receptor 2 -196 to 174del polymorphism influences the susceptibility of Japanese people to gastric cancer. Cancer Sci 2007, 98:1790-1794.
16. Arbour N., Lorenz E., Schutte B., Zabner J., Kline J.N., Jones M., et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet 2000, 25:187-191.
17. Pandey S., Mittal R.D., Srivastava M., Srivastava K., Singh S., Srivastava S., et al. Impact of toll-like receptors [TLR] 2 (-196 to -174 del) and TLR 4 (Asp299Gly, Thr399Ile) in cervical cancer susceptibility in north Indian women. Gynecol Oncol 2009, 114:501-505.
18. González-Reyes S., Fernández J.M., González L.O., Aguirre A., Suárez A., González J.M., et al. Study of TLR3, TLR4, and TLR9 in prostate carcinomas and their association with biochemical recurrence. Cancer Immunol Immunother 2011, 60:217-226.
19. Pinto A., Morello S., Sorrentino R. Lung cancer and toll-like receptors. Cancer Immunol Immunother 2011, 60:1211-1220.
20. Bhattacharya D., Yusuf N. Expression of toll-like receptors on breast tumors: taking a toll on tumor microenvironment. Int J Breast Cancer 2012, [Epub ahead of print].
21. González-Reyes S., Marín L., González L., González L.O., del Casar J.M., Lamelas M.L., et al. Study of TLR3, TLR4 and TLR9 in breast carcinomas and their association with metastasis. BMC Cancer 2010, 10:665.
22. Yang H., Zhou H., Feng P., Zhou X., Wen H., Xie X., et al. Reduced expression of toll-like receptor 4 inhibits human breast cancer cells proliferation and inflammatory cytokines secretion. J Exp Clin Cancer Res 2010, 29:92.
23. Zitvogel L., Tesniere A., Apetoh L., Ghiringhelli F., Kroemer G. Immunological aspects of anticancer chemotherapy. Bull Acad Natl Med 2008, 192:1469-1487.
24. Etokebe G.E., Knezević J., Petricević B., Pavelić J., Vrbanec D., Dembić Z. Single-nucleotide polymorphisms in genes encoding toll-like receptor -2, -3, -4, and -9 in case-control study with breast cancer. Genet Test Mol Biomarkers 2009, 13:729-734.
25. Noguchi E., Nishimura F., Fukai H., Kim J., Ichikawa K., Shibasaki M., et al. An association study of asthma and total serum immunoglobin E levels for toll-like receptor polymorphisms in a Japanese population. Clin Exp Allergy 2004, 34:177-183.
26. Xie W., Huang Y., Xie W., Guo A., Wu W. Bacteria peptidoglycan promoted breast cancer cell invasiveness and adhesiveness by targeting toll-like receptor 2 in the cancer cells. PLoS One 2010, 5:e10850.
27. Huang B., Zhao J., Unkeless J.C., Feng Z.H., Xiong H. TLR signaling by tumor and immune cells: a double-edged sword. Oncogene 2008, 27:218-224.
28. Rakoff-Nahoum S., Medzhitov R. Toll-like receptors and cancer. Nat Rev Cancer 2009, 9:57-63.
29. Fukata M., Hernandez Y., Conduah D., Cohen J., Chen A., Breglio K., et al. Innate immune signaling by toll-like receptor-4 (TLR4) shapes the inflammatory microenvironment in colitis-associated tumors. Inflamm Bowel Dis 2009, 15:997-1006.
30. Zhang Y.B., He F.L., Fang M., Hua T.F., Hu B.D., Zhang Z.H., et al. Increased expression of toll-like receptors 4 and 9 in human lung cancer. Mol Biol Rep 2009, 36:1475-1481.
31. Bergmann C., Bachmann H.S., Bankfalvi A., Lotfi R., Pütter C., Wild C.A., et al. Toll-like receptor 4 single-nucleotide polymorphisms Asp299Gly and Thr399Ile in head and neck squamous cell carcinomas. J Transl Med 2011, 9:139.
32. Apetoh L., Ghiringhelli F., Tesniere A., Obeid M., Ortiz C., Criollo A., et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007, 13:1050-1059.